 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...26272829303132333435363738» |
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date: BOLD 113: This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (clinicaltrials.gov) - Sep 19, 2016
P1, N=20, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jul 2017 --> Nov 2016
- Enrollment open, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Sep 13, 2016
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2017 --> Nov 2016 Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Aug 30, 2016
P2, N=32, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=81 --> 32
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, BRCA Biomarker, Patient reported outcomes, Metastases: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Aug 30, 2016
P2, N=83, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=81 --> 32 Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Deciphera
Enrollment open, Metastases: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (clinicaltrials.gov) - Aug 12, 2016
P1, N=60, Recruiting, Sponsor: Montefiore Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Phase classification, Combination therapy: A Confirmation Study of Eribulin in Combination With Capecitabine (clinicaltrials.gov) - Aug 11, 2016
P1b/2, N=76, Completed, Sponsor: Eisai Limited
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2
- Halaven (eribulin mesylate) / Eisai
New trial, Metastases: Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=38, Recruiting, Sponsor: Centre Oscar Lambret
- | Halaven (eribulin mesylate) / Eisai
New P4 trial, Metastases: PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment (clinicaltrials.gov) - Aug 11, 2016
P4, N=200, Recruiting, Sponsor: Oncologia Medica dell'Ospedale Fatebenefratelli
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Aug 10, 2016
P1, N=40, Recruiting, Sponsor: Corcept Therapeutics
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1b/2 Trial primary completion date: Jun 2016 --> Nov 2016
- ||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial initiation date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Aug 8, 2016
P3, N=328, Not yet recruiting, Sponsor: Immunomedics, Inc.
Trial primary completion date: Jun 2016 --> Nov 2016 Initiation date: Jul 2016 --> Dec 2016
- ||||||| Onzeald (etirinotecan pegol) / Nektar Therap
Trial completion, Trial primary completion date, Metastases: The BEACON Study (Breast Cancer Outcomes With NKTR-102) (clinicaltrials.gov) - Aug 4, 2016
P3, N=852, Completed, Sponsor: Nektar Therapeutics
Initiation date: Jul 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Phase classification, Combination therapy, Metastases: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Jul 29, 2016
P1b/2, N=96, Recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016 Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2
- |||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Jul 23, 2016
P3, N=310, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2 Trial primary completion date: Aug 2016 --> Nov 2016
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Jul 23, 2016
P2, N=39, Recruiting, Sponsor: Virginia G. Kaklamani
Trial primary completion date: Aug 2016 --> Nov 2016 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016
- Halaven (eribulin mesylate) / Eisai
New trial: EMEG-E-01: Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=120, Recruiting, Sponsor: Centre Georges Francois Leclerc
- Halaven (eribulin mesylate) / Eisai
Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=120, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016 Trial primary completion date: Oct 2020 --> Jul 2020
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=29, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Oct 2020 --> Jul 2020 Trial primary completion date: May 2016 --> Aug 2016
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 18, 2016
P2, N=21, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Deciphera
New P1 trial, Metastases: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (clinicaltrials.gov) - Jul 6, 2016
P1, N=60, Not yet recruiting, Sponsor: Montefiore Medical Center
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Jul 1, 2016
P2, N=30, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2018
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jun 27, 2016
P2, N=58, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2016 --> Jun 2018 Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=8, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> May 2018
- ||||||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 23, 2016
P3, N=540, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Dec 2016 --> May 2018 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy, Metastases: GIM11-BERGI: Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients (clinicaltrials.gov) - Jun 15, 2016
P2, N=61, Recruiting, Sponsor: Consorzio Oncotech
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2016
- | Halaven (eribulin mesylate) / Eisai
Phase classification, Combination therapy, Metastases: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Jun 13, 2016
P1b/2, N=95, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Sep 2016 --> Dec 2016 Phase classification: P1/2 --> P1b/2
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Jun 10, 2016
P2, N=162, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1/2 --> P1b/2 Trial primary completion date: Aug 2016 --> Aug 2018
- Halaven (eribulin mesylate) / Eisai
New trial, Metastases: EUFORIA-1: Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - Jun 4, 2016
P=N/A, N=112, Completed, Sponsor: Eisai Farmac
- New P2 trial, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Jun 2, 2016
P2, N=20, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||| Talzenna (talazoparib) / Pfizer
Trial primary completion date, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - May 21, 2016
P3, N=429, Recruiting, Sponsor: Medivation, Inc.
Trial primary completion date: Aug 2016 --> Aug 2018 Trial primary completion date: Jun 2016 --> Jun 2017
- |||| Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 19, 2016
P3, N=540, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Apr 2014 --> Jul 2015
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) - May 16, 2016
P1/2, N=58, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Apr 2014 --> Jul 2015 Trial primary completion date: Dec 2015 --> Dec 2017
- Halaven (eribulin mesylate) / Eisai
New trial, Metastases: EXTER: Extended Treatment in Metastatic Breast Cancer With Eribulin (clinicaltrials.gov) - May 11, 2016
P=N/A, N=45, Completed, Sponsor: Eisai Limited
- || Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Trial primary completion date, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - May 9, 2016
P1/2, N=80, Recruiting, Sponsor: Hope Rugo, MD
Trial primary completion date: Dec 2015 --> Dec 2017 Trial primary completion date: Jan 2016 --> Jan 2018
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date: An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function (clinicaltrials.gov) - May 9, 2016
P1, N=19, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Jan 2016 --> Jan 2018 Trial primary completion date: Jul 2013 --> Jul 2014
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial primary completion date, Combination therapy: A Confirmation Study of Eribulin in Combination With Capecitabine (clinicaltrials.gov) - May 9, 2016
P1/2, N=76, Active, not recruiting, Sponsor: Eisai Limited
Trial primary completion date: Jul 2013 --> Jul 2014 N=116 --> 76 | Trial primary completion date: May 2014 --> May 2015
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: ESKIMO: Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 2, 2016
P4, N=101, Completed, Sponsor: Eisai Korea Inc.
N=116 --> 76 | Trial primary completion date: May 2014 --> May 2015 Active, not recruiting --> Completed
- ||||| Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy, Metastases: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=96, Not yet recruiting, Sponsor: Eisai Inc.
- |||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Apr 25, 2016
P3, N=310, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Aug 2016
- || Xpovio (selinexor) / Karyopharm
Enrollment change, Combination therapy, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 15, 2016
P1, N=470, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2016 --> Aug 2016 N=251 --> 470
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial withdrawal: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 15, 2016
P2, N=0, Withdrawn, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=251 --> 470 N=30 --> 0 | Recruiting --> Withdrawn
- | Halaven (eribulin mesylate) / Eisai
Enrollment open: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=25, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=30 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Apr 4, 2016
P1, N=40, Recruiting, Sponsor: Corcept Therapeutics
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Jun 2016
- ||||| bimiralisib (PQR309) / Torqur
New P1/2 trial, Metastases: PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) (clinicaltrials.gov) - Mar 31, 2016
P1/2, N=60, Not yet recruiting, Sponsor: PIQUR Therapeutics AG
- ||| Halaven (eribulin mesylate) / Eisai
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 30, 2016
P2, N=123, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jan 2016 --> Jun 2016 Initiation date: Nov 2009 --> Feb 2010 | Trial primary completion date: Sep 2014 --> Apr 2011
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date, Metastases: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) (clinicaltrials.gov) - Mar 28, 2016
P2, N=52, Completed, Sponsor: Eisai Co., Ltd.
Initiation date: Nov 2009 --> Feb 2010 | Trial primary completion date: Sep 2014 --> Apr 2011 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Nov 2014
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 23, 2016
P2, N=118, Active, not recruiting, Sponsor: Asan Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Nov 2014 Recruiting --> Active, not recruiting
- Halaven (eribulin mesylate) / Eisai
Trial completion, Monotherapy, Metastases: MERIBEL: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment (clinicaltrials.gov) - Mar 22, 2016
P2a, N=53, Completed, Sponsor: MedSIR
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date, Metastases: First Line Metastatic Breast Cancer Treatment (ESMERALDA) (clinicaltrials.gov) - Mar 18, 2016
P2, N=61, Completed, Sponsor: ARCAGY/ GINECO GROUP
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Aug 2014
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy (clinicaltrials.gov) - Mar 15, 2016
P2, N=128, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Aug 2014 Trial primary completion date: Jul 2016 --> Jun 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination, Combination therapy, Metastases: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (clinicaltrials.gov) - Mar 4, 2016
P2, N=2, Terminated, Sponsor: Katherine Tkaczuk
Trial primary completion date: Jul 2016 --> Jun 2017 N=60 --> 2 | Recruiting --> Terminated; funding withdrawn by sponsor